Semaglutide and Patients Receiving Hemodialysis: Case Reports of Unexpected Benefits for Hyperphosphatemia and Hyperkalemia
- PMID: 38720915
- PMCID: PMC11060791
- DOI: 10.4212/cjhp.3534
Semaglutide and Patients Receiving Hemodialysis: Case Reports of Unexpected Benefits for Hyperphosphatemia and Hyperkalemia
Conflict of interest statement
Competing interests: Raea Dobson has received honoraria from the University of British Columbia for presentation of lectures. No other competing interests were declared.
Figures


References
-
- Saran R, Robinson B, Abbott KC, Agodoa LYC, Albertus P, Avanian J, et al. US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States. Volume 2: ESRD in the United States. Chapter 1: Incidence, prevalence, patient characteristics, and treatment modalities. Am J Kidney Dis. 2017;69(3 Suppl 1):S261–S300. doi: 10.1053/j.ajkd.2016.12.004. - DOI - PMC - PubMed
-
- McFarlane P, Cherney D, Gilbert RE, Senior P. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1–S325. - PubMed
-
- De Boer IH, Caramori ML, Chan JCN, Heerpink HJL, Hurst C, Khunti K, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1–S115. doi: 10.1016/j.kint.2020.06.019. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources